Kinase Inhibitors: Global Markets -- Focus on the U.S.
NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Kinase Inhibitors: Global Markets -- Focus on the U.S.
http://www.reportlinker.com/p0958097/Kinase-Inhibitors-Global-Markets----Focus-on-the-US.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
INTRODUCTION
STUDY OBJECTIVES
BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for kinase inhibitors. The key objective is to present a comprehensive analysis and the future direction of kinase inhibitors to provide an important tool for the usage of these types of enzyme inhibitors.
This report explores present and future strategies within the kinase inhibitors market, which includes tyrosine inhibitors, multi-target kinase inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase inhibitors. The direction of the market, its setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of enzyme inhibitors are also examined in the report.
A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2011 through 2016.
Applications for kinase inhibitors are also discussed separately in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and a summary of patents awarded in each category.
REASONS FOR DOING THIS STUDY
Extensive research in the field of kinase inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of kinase inhibitors in their productions and processes. This has led to the steady market for them.
R&D spending along with increasing competition, patent expiries and new technologies are directing kinase inhibitors to new directions. The new advancements, new product launches and the changing lifestyle have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/ technology in light of the new technologies, growing competition and changing customer needs.
INTENDED AUDIENCE
This study contributes to the areas of market growth in kinase inhibitor manufacture and use. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.
SCOPE OF THE STUDY
The scope of this study encompasses kinase inhibitors in pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand and others countries.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
INFORMATION SOURCES
Many companies active in the kinase inhibitor industry were surveyed to obtain data for this study. Included were manufacturers and end users of kinase inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were conducted. In addition, data were compiled from current financial, trade and government sources.
ABOUT THE AUTHOR
A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are: Reagents for Chromatography; Spectroscopy - An Enduring Market; Advanced Drug Delivery Systems - Technologies and Global Markets; Orthopedic Drugs, Implants and Devices - Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry - The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging - Global Markets; Chiral Technology - Global Markets; Autacoids and Related Drugs - Technologies and Global Markets; Contraceptives - Technologies and Global Markets; Liver Disease Treatments - The Global Market; Hormone Replacement Therapies and Other Hormone Therapies - Global Markets; Cardiovascular Medicine - Diagnostics, Drugs and Devices; and Cancer Therapies - Technologies and Global Markets.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 1
STUDY OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
INTENDED AUDIENCE 1
SCOPE OF THE STUDY 1
METHODOLOGY 2
INFORMATION SOURCES 2
ABOUT THE AUTHOR 2
RELATED BCC RESEARCH REPORTS 2
BCC ONLINE SERVICES 3
DISCLAIMER 3
CHAPTER 2 SUMMARY 5
SUMMARY TABLE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 ($
MILLIONS) 6
SUMMARY FIGURE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016 ($
MILLIONS) 6
CHAPTER 3 OVERVIEW 8
DEFINITIONS 8
ENZYME INHIBITORS 8
WHY ENZYME INHIBITION? 8
USE OF ENZYME INHIBITORS 9
Mechanism of Enzyme Inhibition 9
Types of Enzyme Inhibitors 9
CLASSIFICATION OF ENZYME INHIBITORS 10
TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 10
KINASE INHIBITORS 11
HISTORY OF PROTEIN KINASES 12
TABLE 2 HISTORY OF PROTEIN KINASES 12
TYPES OF KINASE INHIBITORS 13
TABLE 3 TYPES OF KINASE INHIBITORS 13
Small Molecule Inhibitors 13
TABLE 4 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS 14
Antibody (Monoclonal) Inhibitors 14
CLASSIFICATION BY TYPES OF AMINO ACID PHOSPHORYLATION 14
SERINE/THREONINE KINASE INHIBITORS 14
TABLE 5 TYPES OF SERINE/THREONINE KINASE INHIBITORS 15
TYROSINE KINASE INHIBITORS 15
Receptor Tyrosine Kinase (RTK) Inhibitors 16
TABLE 6 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS 16
Non-Receptor Tyrosine Kinase (NRTK) Inhibitors 16
TABLE 7 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS 16
CLASSIFICATION BY SITE OF ACTION 17
TABLE 8 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION 17
CHAPTER 4 REGULATORY ASPECTS 20
TABLE 9 FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012 20
TABLE 10 EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012 21
TABLE 11 SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY
2012 22
TABLE 12 NEW DRUG APPLICATIONS OF KINASE INHIBITORS 23
MARKET LEADERS AND THEIR PRODUCTS FOR KINASE INHIBITORS 24
TABLE 13 LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE
INHIBITORS 24
TABLE 14 LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE
KINASE INHIBITORS 24
TABLE 15 LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE
KINASE INHIBITORS 24
TABLE 16 LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE
KINASE INHIBITORS 25
TABLE 17 LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS 25
CHAPTER 5 NEW DEVELOPMENTS 27
(RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS) 27
TABLE 18 CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS 27
TABLE 19 CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)
TKIS 28
TABLE 20 CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR)
TKIS 28
TABLE 21 CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
(VEGFR) TKIS 28
(NON-RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS) 29
TABLE 22 CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS 29
TABLE 23 CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS 29
TABLE 24 CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS 29
MULTIKINASE INHIBITORS 30
TABLE 25 CLINICAL TRIALS IN MULTIKINASE INHIBITORS 30
SERINE/THREONINE KINASE INHIBITOR 31
TABLE 26 CLINICAL TRIALS IN B-RAF KINASE INHIBITORS 31
TABLE 27 CLINICAL TRIALS IN MAP/MEK INHIBITORS 31
TABLE 28 CLINICAL TRIALS IN PI3K INHIBITORS 31
OTHER KINASE INHIBITOR PRODUCTS UNDER DEVELOPMENT 31
CHAPTER 6 GLOBAL MARKETS 34
MARKET ANALYSIS 34
TABLE 29 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 35
FIGURE 1 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 35
TYROSINE KINASE INHIBITORS 36
TABLE 30 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016 ($
MILLIONS) 36
FIGURE 2 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS 2009-2016 ($ MILLIONS) 36
Receptor Tyrosine Kinase Inhibitors 37
EGFR 37
PDGFR 38
VEGFR 38
HER2 39
Market Overview 39
Market Revenue 40
TABLE 31 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016
($ MILLIONS) 40
FIGURE 3 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 40
Non-Receptor Tyrosine Kinase Inhibitors 40
BCR-ABL 41
Janus Kinase (JAK) Inhibitor 41
Mesenchymal Epithelial Transition Growth Factor (c-MET) 41
Spleen Tyrosine Kinase (SYK) Inhibitors 42
Market Overview 42
Market Revenue 42
TABLE 32 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH
2016 ($ MILLIONS) 43
FIGURE 4 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
($ MILLIONS) 43
Multikinase Inhibitors 43
Market Overview 44
Market Revenue 44
TABLE 33 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016 ($
MILLIONS) 45
FIGURE 5 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($
MILLIONS) 45
SERINE/THREONINE KINASE INHIBITORS 45
mTOR Kinase Inhibitors 45
B RAF 46
RHO Kinase Inhibitors 46
Cyclin Dependant Kinase Inhibitor 46
Aurora Kinase Inhibitors 46
MAP/MEK Kinase Inhibitors 47
JNK Inhibitors 47
Protein Kinase C Inhibitors 47
PI3K Inhibitors 48
Market Overview 48
Market Revenue 48
TABLE 34 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016 ($
MILLIONS) 49
FIGURE 6 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($
MILLIONS) 49
MONOCLONAL ANTIBODY KINASE INHIBITOR 49
Humanized Monoclonal Antibody 50
Chimeric Monoclonal Antibody 50
Human Monoclonal Antibody 51
Market Overview 51
Market Revenue 52
TABLE 35 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH
2016 ($ MILLIONS) 52
FIGURE 7 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, 2009-2016
($ MILLIONS) 52
MARKET SHARE 53
RECEPTOR TYROSINE KINASE INHIBITORS 53
TABLE 36 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53
FIGURE 8 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53
NON-RECEPTOR TYROSINE KINASE INHIBITORS 54
MULTI-TARGET KINASE INHIBITORS 54
TABLE 37 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54
FIGURE 9 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54
SERINE/THREONINE KINASE INHIBITORS 55
TABLE 38 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55
FIGURE 10 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55
MONOCLONAL ANTIBODY KINASE INHIBITORS 56
TABLE 39 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010
(%) 56
FIGURE 11 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION,
2010 (%) 56
MARKET BY APPLICATIONS 57
MARKET REVENUE 58
TABLE 40 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016 ($
MILLIONS) 59
FIGURE 12 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016 ($
MILLIONS) 59
ANTINEOPLASTIC AGENTS 59
TABLE 41 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
THROUGH 2016 ($ MILLIONS) 63
FIGURE 13 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
2009-2016 ($ MILLIONS) 63
IMMUNOSUPPRESSANTS 63
TABLE 42 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
THROUGH 2016 ($ MILLIONS) 64
FIGURE 14 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016 ($ MILLIONS) 64
AGE-RELATED MACULAR DEGENERATION 65
TABLE 43 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, THROUGH 2016 ($ MILLIONS) 66
FIGURE 15 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016 ($ MILLIONS) 66
MARKET SHARE 67
TABLE 44 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 67
FIGURE 16 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 67
CHAPTER 7 MARKETS IN THE UNITED STATES 69
MARKET ANALYSIS 69
TABLE 45 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69
FIGURE 17 U.S. MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69
TYROSINE KINASE INHIBITORS 70
TABLE 46 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 71
FIGURE 18 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 71
Receptor Tyrosine Kinase Inhibitors 71
EGFR 72
PDGFR 72
VEGFR 72
HER2 73
Market Overview 73
Market Revenue 74
TABLE 47 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016 ($
MILLIONS) 74
FIGURE 19 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 74
Non-Receptor Tyrosine Kinase Inhibitors 75
BCR-ABL 75
Janus Kinase (JAK) Inhibitor 76
Mesenchymal Epithelial Transition Growth Factor (c-MET) 76
Spleen Tyrosine Kinase (SYK) Inhibitors 76
Market Overview 77
Market Revenue 77
TABLE 48 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH
2016 ($ MILLIONS) 77
FIGURE 20 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 77
Multikinase Inhibitors 78
Market Overview 78
Market Revenue 79
TABLE 49 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, THROUGH 2016 ($
MILLIONS) 80
FIGURE 21 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($ MILLIONS) 80
SERINE/THREONINE KINASE INHIBITORS 80
M TOR Kinase Inhibitors 80
B RAF 81
RHO Kinase Inhibitors 81
Cyclin Dependant Kinase Inhibitor 81
Aurora Kinase Inhibitors 81
MAP/MEK Kinase Inhibitors 82
JNK Inhibitors 82
Protein Kinase C Inhibitors 82
PI3K Inhibitors 83
Market Overview 83
Market Revenue 84
TABLE 50 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, THROUGH 2016 ($
MILLIONS) 84
FIGURE 22 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 85
MONOCLONAL ANTIBODY KINASE INHIBITOR 85
Humanized Monoclonal Antibody 86
Chimeric Monoclonal Antibody 87
Human Monoclonal Antibody 87
Market Overview 87
Market Revenue 88
TABLE 51 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH 2016
($ MILLIONS) 88
FIGURE 23 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR 2009-2016 ($
MILLIONS) 88
MARKET SHARE OF INDUSTRY LEADERS IN U.S 89
RECEPTOR TYROSINE KINASE INHIBITORS 89
TABLE 52 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 89
FIGURE 24 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 89
NON-RECEPTOR TYROSINE KINASE INHIBITORS 90
MULTI-TARGET KINASE INHIBITORS 90
TABLE 53 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,
2010 (%) 90
FIGURE 25 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,
2010 (%) 90
SERINE/ THREONINE KINASE INHIBITORS 91
TABLE 54 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 91
FIGURE 26 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 91
ANTIBODY KINASE INHIBITORS 92
TABLE 55 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010
(%) 92
FIGURE 27 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010
(%) 92
MARKET APPLICATIONS 93
MARKET REVENUE 94
TABLE 56 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, THROUGH 2016 ($
MILLIONS) 94
FIGURE 28 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($
MILLIONS) 94
ANTINEOPLASTIC AGENTS 95
TABLE 57 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
THROUGH 2016 ($ MILLIONS) 98
FIGURE 29 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
2009-2016 ($ MILLIONS) 98
IMMUNOSUPPRESSANTS 99
TABLE 58 U.S. MARKET FOR KINASE INHIBITORS USED AS
IMMUNOSUPPRESSANTS,THROUGH 2016 ($ MILLIONS) 100
FIGURE 30 U.S. MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016 ($ MILLIONS) 100
AGE-RELATED MACULAR DEGENERATION 101
TABLE 59 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, THROUGH 2016 ($ MILLIONS) 102
FIGURE 31 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016 ($ MILLIONS) 102
MARKET SHARE 103
TABLE 60 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103
FIGURE 32 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103
CHAPTER 8 PATENT ANALYSIS 105
PATENTS BY YEAR 105
TABLE 61 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 105
FIGURE 33 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 105
FIGURE 34 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 (%) 106
PATENTS BY CATEGORY 106
TABLE 62 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY
2012 107
FIGURE 35 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY
2012 107
PATENTS BY TYPE 107
TABLE 63 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF
FEBRUARY 2012 107
FIGURE 36 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF
FEBRUARY 2012 108
TABLE 64 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END
OF FEBRUARY 2012 108
FIGURE 37 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END
OF FEBRUARY 2012 108
PATENTS BY COMPANY 109
TABLE 65 NUMBER OF U.S. PATENTS BY COMPANY FOR INDUSTRIAL ENZYMES, 2008 TO
END OF FEBRUARY 2012 109
PATENTS BY COUNTRY 110
TABLE 66 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END
OF FEBRUARY 2012 110
FIGURE 38 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO
END OF FEBRUARY 2012 110
TABLE 67 PATENT SHARE BY COUNTRY FOR KINASE INHIBITORS, 2010–2012 (%) 111
FIGURE 39 PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010–2012 (%) 111
PATENTS BY ASSIGNEE 112
TABLE 68 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF
FEBRUARY 2012 112
FIGURE 40 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF
FEBRUARY 2012 112
CHAPTER 9 CURRENT STATUS 115
CANCER AND KINASE INHIBITORS 115
MULTIPLE SINGLE KINASE INHIBITORS VERSUS SINGLE MULTIKINASE INHIBITORS 115
EFFICACY 116
RESISTANCE 116
PHARMACOKINETICS 117
Selectivity 117
TUMOR MICROENVIRONMENT 117
TOXICITY 118
FUTURE DIRECTIONS 118
CHAPTER 10 COMPANY PROFILES 120
ABBOTT LABORATORIES 120
AMGEN INC. 120
ARQULE, INC. 121
ARRAY BIOPHARMA 121
ASTRAZENECA 121
AVEO PHARMACEUTICALS, INC. 122
BAYER AG 122
BRISTOL-MYERS SQUIBB 123
BOEHRINGER INGELHEIM 123
CYTRX CORPORATION 123
EISAI INC 124
ETON BIOSCIENCE, INC. 124
EXELIXIS, INC. 124
GLAXOSMITHKLINE 125
MERCK SERONO SA 125
NOVARTIS INTERNATIONAL AG 126
OSI PHARMACEUTICALS LLC 126
PFIZER 127
ROCHE GROUP 127
S*BIO PTE LTD 128
SANOFI-AVENTIS 128
TAKEDA PHARMACEUTICALS 129
CHAPTER 11 APPENDIX: ABBREVIATIONS 131
LIST OF TABLES
SUMMARY TABLE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 ($
MILLIONS) 6
TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 10
TABLE 2 HISTORY OF PROTEIN KINASES 12
TABLE 3 TYPES OF KINASE INHIBITORS 13
TABLE 4 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS 14
TABLE 5 TYPES OF SERINE/THREONINE KINASE INHIBITORS 15
TABLE 6 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS 16
TABLE 7 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS 16
TABLE 8 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION 17
TABLE 9 FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012 20
TABLE 10 EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012 21
TABLE 11 SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY
2012 22
TABLE 12 NEW DRUG APPLICATIONS OF KINASE INHIBITORS 23
TABLE 13 LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE
INHIBITORS 24
TABLE 14 LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE
KINASE INHIBITORS 24
TABLE 15 LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE
KINASE INHIBITORS 24
TABLE 16 LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE KINASE
INHIBITORS 25
TABLE 17 LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS 25
TABLE 18 CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS 27
TABLE 19 CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)
TKIS 28
TABLE 20 CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR)
TKIS 28
TABLE 21 CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
(VEGFR) TKIS 28
TABLE 22 CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS 29
TABLE 23 CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS 29
TABLE 24 CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS 29
TABLE 25 CLINICAL TRIALS IN MULTIKINASE INHIBITORS 30
TABLE 26 CLINICAL TRIALS IN B-RAF KINASE INHIBITORS 31
TABLE 27 CLINICAL TRIALS IN MAP/MEK INHIBITORS 31
TABLE 28 CLINICAL TRIALS IN PI3K INHIBITORS 31
TABLE 29 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 35
TABLE 30 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016 ($
MILLIONS) 36
TABLE 31 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016 ($
MILLIONS) 40
TABLE 32 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH
2016 ($ MILLIONS) 43
TABLE 33 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016 ($
MILLIONS) 45
TABLE 34 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016 ($
MILLIONS) 49
TABLE 35 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH
2016 ($ MILLIONS) 52
TABLE 36 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53
TABLE 37 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54
TABLE 38 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55
TABLE 39 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010
(%) 56
TABLE 40 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016 ($
MILLIONS) 59
TABLE 41 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
THROUGH 2016 ($ MILLIONS) 63
TABLE 42 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
THROUGH 2016 ($ MILLIONS) 64
TABLE 43 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, THROUGH 2016 ($ MILLIONS) 66
TABLE 44 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 67
TABLE 45 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69
TABLE 46 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 71
TABLE 47 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016 ($
MILLIONS) 74
TABLE 48 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016
($ MILLIONS) 77
TABLE 49 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, THROUGH 2016 ($
MILLIONS) 80
TABLE 50 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, THROUGH 2016 ($
MILLIONS) 84
TABLE 51 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH 2016
($ MILLIONS) 88
TABLE 52 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 89
TABLE 53 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,
2010 (%) 90
TABLE 54 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 91
TABLE 55 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010 (%) 92
TABLE 56 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, THROUGH 2016 ($
MILLIONS) 94
TABLE 57 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
THROUGH 2016 ($ MILLIONS) 98
TABLE 58 U.S. MARKET FOR KINASE INHIBITORS USED AS
IMMUNOSUPPRESSANTS,THROUGH 2016 ($ MILLIONS) 100
TABLE 59 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, THROUGH 2016 ($ MILLIONS) 102
TABLE 60 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103
TABLE 61 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 105
TABLE 62 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY
2012 107
TABLE 63 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF FEBRUARY
2012 107
TABLE 64 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END OF
FEBRUARY 2012 108
TABLE 65 NUMBER OF U.S. PATENTS BY COMPANY FOR INDUSTRIAL ENZYMES, 2008 TO
END OF FEBRUARY 2012 109
TABLE 66 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END
OF FEBRUARY 2012 110
TABLE 67 PATENT SHARE BY COUNTRY FOR KINASE INHIBITORS, 2010–2012 (%) 111
TABLE 68 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF
FEBRUARY 2012 112
LIST OF FIGURES
INHIBITORS MARKET, 2009-2016 ($
MILLIONS) 6
FIGURE 1 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 35
FIGURE 2 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS 2009-2016 ($ MILLIONS) 36
FIGURE 3 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 40
FIGURE 4 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
($ MILLIONS) 43
FIGURE 5 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($
MILLIONS) 45
FIGURE 6 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($
MILLIONS) 49
FIGURE 7 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 52
FIGURE 8 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53
FIGURE 9 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54
FIGURE 10 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55
FIGURE 11 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010
(%) 56
FIGURE 12 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016 ($
MILLIONS) 59
FIGURE 13 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
2009-2016 ($ MILLIONS) 63
FIGURE 14 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016 ($ MILLIONS) 64
FIGURE 15 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016 ($ MILLIONS) 66
FIGURE 16 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 67
FIGURE 17 U.S. MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69
FIGURE 18 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 71
FIGURE 19 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 74
FIGURE 20 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 77
FIGURE 21 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($ MILLIONS) 80
FIGURE 22 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016 ($
MILLIONS) 85
FIGURE 23 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR 2009-2016 ($
MILLIONS) 88
FIGURE 24 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 89
FIGURE 25 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,
2010 (%) 90
FIGURE 26 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 91
FIGURE 27 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010
(%) 92
FIGURE 28 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($ MILLIONS) 94
FIGURE 29 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,
2009-2016 ($ MILLIONS) 98
FIGURE 30 U.S. MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016 ($ MILLIONS) 100
FIGURE 31 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016 ($ MILLIONS) 102
FIGURE 32 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103
FIGURE 33 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 105
FIGURE 34 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 (%) 106
FIGURE 35 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY
2012 107
FIGURE 36 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF
FEBRUARY 2012 108
FIGURE 37 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END
OF FEBRUARY 2012 108
FIGURE 38 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END
OF FEBRUARY 2012 110
FIGURE 39 PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010–2012 (%) 111
FIGURE 40 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF
FEBRUARY 2012 112
To order this report:
Therapy Industry: Kinase Inhibitors: Global Markets -- Focus on the U.S.
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article